Medline (NASDAQ:MDLN) Price Target Raised to $49.00

Posted by George Bondi on Nov 5th, 2026

Medline (NASDAQ:MDLN – Get Free Report) had its target price raised by equities research analysts at UBS Group from $43.00 to $49.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group‘s price objective indicates a potential upside of 23.24% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. decreased their price target on shares of Medline from $53.00 to $46.00 and set an “overweight” rating for the company in a research note on Wednesday, August 12th. Mizuho cut their price objective on shares of Medline from $48.00 to $45.00 and set an “outperform” rating on the stock in a research report on Thursday, October 22nd. Stifel Nicolaus cut their price objective on shares of Medline from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. BMO Capital Markets restated an “outperform” rating and set a $47.00 target price on shares of Medline in a report on Thursday, August 6th. Finally, Tigress Financial decreased their target price on shares of Medline from $62.00 to $55.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Twenty-three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Medline has a consensus rating of “Moderate Buy” and a consensus price target of $46.08.

Read Our Latest Report on Medline

Medline Stock Down 1.5%

Shares of MDLN stock traded down $0.59 on Thursday, hitting $39.76. 14,219,667 shares of the stock were exchanged, compared to its average volume of 7,779,645. The company has a current ratio of 4.33, a quick ratio of 2.61 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $52.27 billion and a P/E ratio of 50.33. Medline has a fifty-two week low of $31.37 and a fifty-two week high of $50.88. The business has a 50-day moving average of $34.68 and a 200 day moving average of $39.51.

Medline (NASDAQ:MDLN – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.12. The firm had revenue of $7.86 billion during the quarter. Equities analysts anticipate that Medline will post 1.49 EPS for the current year.

Insider Buying and Selling

In other Medline news, major shareholder Private Ltd Gic sold 2,570,999 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $35.35, for a total value of $90,884,814.65. Following the completion of the transaction, the insider directly owned 20,231,483 shares in the company, valued at $715,182,924.05. This trade represents a 11.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 8,538,960 shares of company stock worth $302,807,442 over the last ninety days. Corporate insiders own 0.81% of the company’s stock.

Institutional Investors Weigh In On Medline

Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its holdings in shares of Medline by 68.3% in the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after buying an additional 254 shares during the last quarter. Whipplewood Advisors LLC bought a new position in shares of Medline in the first quarter valued at $30,000. Reyes Financial Architecture Inc. acquired a new position in Medline during the third quarter worth $30,000. NewEdge Advisors LLC increased its holdings in Medline by 100.0% during the second quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock worth $37,000 after buying an additional 475 shares during the last quarter. Finally, Allworth Financial LP raised its position in Medline by 86.2% during the second quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock worth $41,000 after acquiring an additional 487 shares in the last quarter.

Key Medline News

Here are the key news stories impacting Medline this week:

Positive Sentiment: Quarterly results beat expectations. Medline reported third-quarter earnings of $0.44 per share, versus the $0.32 consensus estimate, on $7.86 billion in revenue. Reports also said the company raised its full-year growth outlook. Medline Q3 2026 earnings
Positive Sentiment: Analyst price targets moved higher. Citigroup raised its target to $47 and assigned a Buy rating; Leerink Partners raised its target to $46 and maintained an Outperform rating. BTIG reaffirmed Buy with a $55 target, and Barclays also issued a Buy rating. The upgrades suggest analysts see further potential after the results. Citigroup rating Leerink Partners rating BTIG rating Barclays rating
Positive Sentiment: Share repurchases provided another supportive signal. Coverage highlighted a $1 billion share-buyback program alongside the earnings beat. Medline Q3 beat and buybacks
Neutral Sentiment: Medline plans to raise prices in 2027 to help offset inflation. The changes could support margins, though their effect on customer demand is uncertain; the company also reaffirmed its 2026 adjusted EBITDA outlook. Medline pricing plans and Q3 results
Negative Sentiment: A law firm announced an investigation into potential securities-law violations related to alleged product-quality issues. The announcement is an overhang, although it is an investigation notice rather than a finding of wrongdoing. Medline investigation announcement

Medline Company Profile

(Get Free Report)

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.